Healthcare Analyst Tsao, along with John Renger, Chief Scientific Officer at Cerevel, discuss the Company’s three programs, kappa opioid receptor antagonist (KORA), M4 agonist and PDE4, and the Companys approach to drug development on the "Emerging Ideas in Biopharma" conference call to be held on March 14 at 11 am hosted by H.C. Wainwright.Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CERE:
- Cerevel Therapeutics to participate in a conference call with H.C. Wainwright
- Cerevel Therapeutics price target lowered to $26 from $28 at Mizuho
- Cerevel Therapeutics to Present at the 43rd Annual Cowen Health Care Conference
- Cerevel Therapeutics price target lowered to $45 from $48 at H.C. Wainwright
- Wells Fargo downgrades Cerevel on lack of catalysts until 2024
